RESEARCH 研究の報告

2024.2.1

Clinical significance of antinuclear antibody as prognostic marker for first-line pembrolizumab in advanced non-small cell lung cancer.

著者 Mouri A, Kaira K, Yamaguchi O, Hashimoto K, Miura Y, Shiono A, Kawasaki T, Kobayashi K, Imai H, Kagamu H.

Int J Clin Oncol. 2024 Feb;29(2):124-133. doi: 10.1007/s10147-023-02445-4. Epub 2023 Dec 31.

PMID: 38160406

2024.1.19

Clinical impact of inflammatory and nutrition index based on metabolic tumor activity in non‑small cell lung cancer treated with immunotherapy.

著者 Ito K, Hashimoto K, Kaira K, Yamaguchi O, Mouri A, Shiono A, Miura Y, Kobayashi K, Imai H, Kuji I, Kagamu H.

Oncol Lett. 2024 Jan 19;27(3):110. doi: 10.3892/ol.2024.14243. eCollection 2024 Mar.

PMID: 38304175 Free PMC article.

2024.1.10

Risk Factors for Bleeding Events in Japanese Patients with Advanced Lung Cancer: Data from the Rising-VTE/NEJ037 Study.

著者 Kawakado K, Tsubata Y, Hotta T, Yamasaki M, Ishikawa N, Fujitaka K, Kubota T, Kobayashi K, Isobe T.

Cancers (Basel). 2024 Jan 10;16(2):301. doi: 10.3390/cancers16020301.

PMID: 38254791; PMCID: PMC10814048.